Sinovac Biotech, Ltd. (NASDAQ:SVA) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, ValuEngine upgraded shares of Sinovac Biotech from a “sell” rating to a “hold” rating in a report on Friday, June 30th.

Shares of Sinovac Biotech (NASDAQ SVA) traded up 0.59% on Friday, hitting $6.80. 79,018 shares of the stock were exchanged. The stock’s 50-day moving average is $6.79 and its 200-day moving average is $6.00. Sinovac Biotech has a 1-year low of $4.60 and a 1-year high of $6.94. The stock’s market cap is $387.38 million.

WARNING: “Sinovac Biotech, Ltd. (SVA) Downgraded by BidaskClub” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/09/sinovac-biotech-ltd-sva-downgraded-by-bidaskclub.html.

Several hedge funds have recently made changes to their positions in the company. Morgan Stanley raised its holdings in shares of Sinovac Biotech by 86,309.9% in the first quarter. Morgan Stanley now owns 2,721,912 shares of the biopharmaceutical company’s stock valued at $15,597,000 after purchasing an additional 2,718,762 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Sinovac Biotech by 8.0% in the second quarter. Renaissance Technologies LLC now owns 1,814,300 shares of the biopharmaceutical company’s stock valued at $12,247,000 after purchasing an additional 134,810 shares during the last quarter. GLG Partners LP raised its holdings in shares of Sinovac Biotech by 144.8% in the second quarter. GLG Partners LP now owns 282,611 shares of the biopharmaceutical company’s stock valued at $1,908,000 after purchasing an additional 167,165 shares during the last quarter. Eqis Capital Management Inc. raised its holdings in shares of Sinovac Biotech by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 156,779 shares of the biopharmaceutical company’s stock valued at $1,058,000 after purchasing an additional 983 shares during the last quarter. Finally, Spark Investment Management LLC raised its holdings in shares of Sinovac Biotech by 62.5% in the first quarter. Spark Investment Management LLC now owns 54,600 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 21,000 shares during the last quarter. Institutional investors own 30.69% of the company’s stock.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.